Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Lopinavir/ritonavir for the treatment of COVID-19: A living systematic review protocol

View ORCID ProfileFrancisca Verdugo-Paiva, View ORCID ProfileAriel Izcovich, View ORCID ProfileMartín Ragusa, View ORCID ProfileGabriel Rada
doi: https://doi.org/10.1101/2020.04.11.20062109
Francisca Verdugo-Paiva
1Fundación Epistemonikos, Santiago, Chile
2UC Evidence Center, Cochrane Chile Associated Center, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Francisca Verdugo-Paiva
  • For correspondence: fverdugo@epistemonikos.org
Ariel Izcovich
3Internal Medicine Service, German Hospital, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ariel Izcovich
Martín Ragusa
3Internal Medicine Service, German Hospital, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martín Ragusa
Gabriel Rada
1Fundación Epistemonikos, Santiago, Chile
2UC Evidence Center, Cochrane Chile Associated Center, Pontificia Universidad Católica de Chile, Santiago, Chile
4Internal Medicine Department, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gabriel Rada
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Objective To assess the efficacy and safety of lopinavir/ritonavir for the treatment of patients with COVID-19.

Design This is the protocol of a living systematic review.

Data sources We will conduct searches in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature and in a centralised repository in L·OVE (Living OVerview of Evidence). L·OVE is a platform that maps PICO questions to evidence from Epistemonikos database. In response to the COVID-19 emergency, L·OVE was adapted to expand the range of evidence it covers and customised to group all COVID-19 evidence in one place. The search will cover the period until the day before submission to a journal.

Eligibility criteria for selecting studies and methods We adapted an already published common protocol for multiple parallel systematic reviews to the specificities of this question.

We will include randomised trials evaluating the effect of lopinavir/ritonavir— as monotherapy or in combination with other drugs — versus placebo or no treatment in patients with COVID-19. Randomised trials evaluating lopinavir/ritonavir in infections caused by other coronaviruses, such as MERS-CoV and SARS-CoV, and non-randomised studies in COVID-19 will be searched in case no direct evidence from randomised trials is found, or if the direct evidence provides low- or very low-certainty for critical outcomes.

Two reviewers will independently screen each study for eligibility, extract data, and assess the risk of bias. We will perform random-effects meta-analyses and use GRADE to assess the certainty of the evidence for each outcome.

A living, web-based version of this review will be openly available during the COVID-19 pandemic. We will resubmit it if the conclusions change or there are substantial updates.

Ethics and dissemination No ethics approval is considered necessary. The results of this review will be widely disseminated via peer-reviewed publications, social networks and traditional media.

PROSPERO Registration Submitted to PROSPERO (awaiting ID allocation).

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Submitted to PROSPERO (awaiting ID allocation).

Clinical Protocols

https://www.medwave.cl/link.cgi/English/Original/Protocols/7867.act

Funding Statement

This project was not commissioned by any organisation and did not receive external funding. Epistemonikos Foundation is providing training, support and tools at no cost for all the members of the COVID-19 L·OVE Working Group.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • COVID-19 L·OVE Working Group

Data Availability

All data related to the project will be available. Epistemonikos Foundation will grant access to data.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 17, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Lopinavir/ritonavir for the treatment of COVID-19: A living systematic review protocol
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Lopinavir/ritonavir for the treatment of COVID-19: A living systematic review protocol
Francisca Verdugo-Paiva, Ariel Izcovich, Martín Ragusa, Gabriel Rada
medRxiv 2020.04.11.20062109; doi: https://doi.org/10.1101/2020.04.11.20062109
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Lopinavir/ritonavir for the treatment of COVID-19: A living systematic review protocol
Francisca Verdugo-Paiva, Ariel Izcovich, Martín Ragusa, Gabriel Rada
medRxiv 2020.04.11.20062109; doi: https://doi.org/10.1101/2020.04.11.20062109

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (578)
  • Anesthesia (139)
  • Cardiovascular Medicine (1942)
  • Dentistry and Oral Medicine (252)
  • Dermatology (184)
  • Emergency Medicine (331)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (697)
  • Epidemiology (11095)
  • Forensic Medicine (8)
  • Gastroenterology (621)
  • Genetic and Genomic Medicine (3163)
  • Geriatric Medicine (307)
  • Health Economics (561)
  • Health Informatics (2041)
  • Health Policy (862)
  • Health Systems and Quality Improvement (782)
  • Hematology (310)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12707)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2980)
  • Nursing (163)
  • Nutrition (462)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1549)
  • Ophthalmology (476)
  • Orthopedics (185)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (402)
  • Pediatrics (910)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2780)
  • Public and Global Health (5588)
  • Radiology and Imaging (1090)
  • Rehabilitation Medicine and Physical Therapy (631)
  • Respiratory Medicine (758)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (289)
  • Surgery (343)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (132)